Axsome Soars After Depression Trial Success

$1bn+ Peak Revenues Forecast Once Approved

 
• By Andrew McConaghie

Axsome is set to file for approval in the second half of 2020.

Brain_Stress
New depression treatments remain rare, though J&J's Spravato gained approval earlier this year

More from Clinical Trials

More from R&D